Revolutionary NMN Treatment: Can NMN Revolutionize Treatment for AMD & Dry Eye Disease?

While existing therapies have made significant strides in managing these diseases, they often come with limitations and potential side effects. Therefore, the exploration for more comprehensive, safer, and more effective solutions is ongoing. 

In this context, Nicotinamide Mononucleotide (NMN), a crucial molecule involved in our body's energy metabolism, has come under the spotlight. Emerging research is beginning to highlight its potential benefits for eye health, specifically concerning AMD and DED.

This article will:

• Examine the relationship between NMN and eye health, particularly its role in combating Age-Related Macular Degeneration and Dry Eye Disease.

• Discuss the potential benefits of NMN supplementation for managing and possibly improving these conditions.

• Review current research findings on the effectiveness of NMN in dealing with AMD and DED.

By delving into these areas, we aim to provide a clearer understanding of the potential of NMN as a promising supplement for eye health, shedding new light on preventive measures and therapeutic options for those grappling with AMD and DED.

What Are Age-Related Macular Degeneration (AMD) and Dry Eye Disease (DED)?

AMD, the leading cause of vision loss, involves the deterioration of the macula, responsible for sharp, central vision. Dry AMD, the most common form, involves the thinning of the macula, while wet AMD features abnormal blood vessels under the retina causing rapid vision loss.

DED, on the other hand, is a complex disorder causing discomfort and visual disturbances due to factors such as inadequate tear production and excessive tear evaporation. Depending on diagnostic criteria, DED affects between 5% and 50% of adults and significantly impacts patients' quality of life. 

Treatment for both AMD and DED involves medical interventions, lifestyle changes, and occasionally surgery. However, these treatments don't always fully address the underlying causes. Hence, researchers are investigating the potential benefits of Nicotinamide Mononucleotide (NMN) supplementation as an alternative treatment option. [1,2] 

The Intriguing Science of NMN, AMD, and DED

The following section delves into the latest research on how NMN might help in treating these prevalent eye diseases, setting the stage for potential breakthroughs in eye health.

NMN Is a Potential Breakthrough in Dry Eye Disease Treatment

Dry Eye Disease can cause the surface of your eyes to get injured, and if not treated properly, it could harm your vision.

Scientists have been searching for a better way to treat this condition. They believe Nicotinamide Mononucleotide (NMN) might help. NMN has been found to help cells stay healthy in other eye conditions, so researchers are exploring if it can also help with Dry Eye Disease.

A group of scientists in China conducted a study published in the Journal of inflammation research in 2021 on mouse eye cells. They found that NMN helped protect the eye cells from damage caused by high salt levels, a condition similar to what happens in Dry Eye Disease. NMN also reduced inflammation (swelling and redness) in the eye cells.

This happened because NMN increased levels of a helpful molecule called NAD+ in the cells. This molecule helps keep cells healthy and also activates a protein called Sirtuin1 (SIRT1) that aids in healing.

The scientists also found that NMN could guide immune cells, known as macrophages, to shift from causing damage to promoting healing. This is an essential process in recovering from any damage or injury.

These findings are promising, but we still need more studies to confirm if NMN can help humans with Dry Eye Disease. If it works, NMN could be used alongside existing treatments to help people with this uncomfortable and potentially vision-damaging condition. [3] 

NMN May Help Against Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the main cause of vision loss in older people. People with AMD struggle with reading, recognizing faces and seeing fine details. Sadly, only 10% of AMD cases can be treated currently, which are the "wet" AMD cases. The remaining 90% of "dry" AMD cases, where cells in the retina of the eye are lost, have no treatment.

A study published in Redox Biology in 2020 shows that fixing problems in the mitochondria (the energy generator of a cell) can help treat dry AMD. A team of scientists gave four different substances to cells from AMD patients: N-acetyl-L-cysteine (NAC), rapamycin, pyrroloquinoline quinone (PQQ), and nicotinamide mononucleotide (NMN). Each substance worked differently in each patient, suggesting that personalizing treatment might be a good idea for AMD.

These substances were chosen for their effects on the mitochondria. They help increase the amount of energy the cell can produce, get rid of any damaged mitochondria, and help keep the cell healthy. When the scientists treated the cells, they found that rapamycin, PQQ, and NMN improved the cells' energy production.

But the effect wasn't the same in all patients – some had a lot of improvement, while others only had a little. The researchers think that creating a mix of these substances could lead to better results. This study gives hope that personalized treatment options for AMD might be possible in the future. [4] 

NMN May Shield Eye Cells from Damage After Retinal Detachment

Scientists have found a substance that might protect the eyes as people get older and suffer from eye problems. These problems include conditions like age-related macular degeneration, diabetic eye disease, and detached retina, which can cause severe vision loss. In these conditions, the cells in our eyes that react to light (called photoreceptors) get damaged and start dying. Currently, there are no medicines to prevent this.

A team of researchers at Harvard Medical School found that a substance called Nicotinamide Mononucleotide (NMN) could protect these light-reacting cells when the retina gets detached, which often leads to blindness. Their tests in mice showed that NMN reduced cell death, lowered eye inflammation, and increased the level of substances that fight cell damage.

NMN works by increasing the level of a molecule named NAD+, which is important for the energy production, DNA maintenance, and cell growth in our bodies. It seems that NAD+ might play a big role in preventing eye diseases. Scientists found that having more NAD+ could protect the eyes from damage caused by light.

When the team gave mice NMN, they saw less death of the eye cells after the retina got detached. They also found that NMN reduced cell damage and increased the level of a protective substance called HO-1. The higher levels of HO-1 depended on the activity of an enzyme called SIRT1. Therefore, they think NMN might help by increasing NAD+ and SIRT1 levels, which in turn increases HO-1 levels.

These findings suggest that NMN could potentially help treat age-related eye diseases. But more research is needed to see if this also works in humans. If it does, NMN could offer hope for people suffering from conditions that cause severe vision loss. [5] 

Conclusion

The investigation into NMN's potential benefits shows encouraging possibilities for managing conditions like AMD and DED. Preliminary studies suggest that NMN could shield eye cells and diminish inflammation, raising optimism for superior treatments.

While we anticipate further research in human subjects, it's noteworthy that high-quality NMN supplements, such as HealthspanX Ultra Pure NMN™, are already accessible. This suggests a promising future where such supplements could play a vital role in innovative therapies for these prevalent eye diseases.

Citations